THE DEFINITIVE GUIDE TO AGO TUMOR

Molecular typing is predicated on molecular genetic tests and isn't still routinely accessible. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple detrimental) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 could possibly be handy,